PTTG1-driven self-amplifying loop with SP1 and ENO1 promotes IRF4-mediated myeloma progression and bone destruction
TL;DR
A novel mechanistic insight is introduced into the pathogenesis of myeloma and bone deterioration and disruption of the ENO1–PTTG1 interaction is identified as a potential dual-targeting therapeutic strategy, demonstrating significant efficacy in curbing myeloma progression and osteolytic lesions.
Abstract
Multiple myeloma (MM) is a neoplastic disorder of plasma cells within the hematopoietic system and is characterized by osteolytic lesions. Despite significant advances, the molecular underpinnings of myeloma and its associated bone pathologies remain elusive, and there is an unmet need for effective targeted therapies. Our research uncovers upregulation of pituitary tumor-transforming gene 1 (PTTG1) in myeloma cells, which synergizes with transcription factor specificity protein 1 (SP1) to enhance its nuclear accumulation and consequently elevate the expression of glycolytic enzyme enolase-1 (ENO1). Intriguingly, ENO1, in a non-catalytic role, complexes with PTTG1/SP1, thereby amplifying the transcriptional activity of interferon regulatory factor 4 (IRF4). This cascade accelerates myeloma progression and exacerbates osteolytic lesions. Notably, IRF4 binds to the PTTG1 promoter, establishing a positive feedback loop that amplifies PTTG1 expression. Our study introduces a novel mechanistic insight into the pathogenesis of myeloma and bone deterioration and identifies disruption of the ENO1–PTTG1 interaction as a potential dual-targeting therapeutic strategy. The use of blocking peptides to interfere with this interaction demonstrates significant efficacy in curbing myeloma progression and osteolytic lesions, offering a promising avenue for clinical intervention.